TR is a novel synthetic peptide designed as a dual agonist for the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. It is primarily being studied for its potential therapeutic applications in managing type 2 diabetes and obesity. By mimicking the effects of both GLP-1 and GIP, TR effectively influences insulin secretion, glucagon suppression, and appetite regulation, making it an innovative candidate in the realm of metabolic therapeutics.